Part 2 evaluated T-DXd in combination with a fluoropyrimidine (5-fluorouracil (5-FU) or capecitabine (CAPE)) and pembrolizumab in previously untreated HER2+ gastric cancer. The gene discussed is ERBB2; the disease is gastric cancer.